| Literature DB >> 24970328 |
Ningning Ma, Sarah Zalwango, LaShaunda L Malone, Mary Nsereko, Eddie M Wampande, Bonnie A Thiel, Brenda Okware, Robert P Igo, Moses L Joloba, Ezekiel Mupere, Harriet Mayanja-Kizza, W Henry Boom, Catherine M Stein1.
Abstract
BACKGROUND: Despite sustained exposure to a person with pulmonary tuberculosis (TB), some M. tuberculosis (Mtb) exposed individuals maintain a negative tuberculin skin test (TST). Our objective was to characterize these persistently negative TST (PTST-) individuals and compare them to TST converters (TSTC) and individuals who are TST positive at study enrollment.Entities:
Mesh:
Year: 2014 PMID: 24970328 PMCID: PMC4091673 DOI: 10.1186/1471-2334-14-352
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Population demographics
| | | | | ||||
| 2 years or less | 19 (13.4%) | 22 (13.1%) | 103(11.4%) | 144(11.9%) | | | |
| >2 and equal to 5 | 27(19.0%) | 24(14.3%) | 93(10.3%) | 144(11.9%) | | | |
| >5 or less than 15 | 65 (45.8%) | 47 (28.0%) | 237 (26.3%) | 349 (28.8%) | | | |
| >15 | 31 (21.8%) | 75 (44.6%) | 467 (51.9%) | 573 (47.3%) | | | |
| All | 142 | 168 | 900 | 1210 | < 0.0005* | <0.0005* | < 0.0005* |
| | | ||||||
| Female | 73 (51.4%) | 98 (58.3%) | 488 (54.2%) | 659 (54.5%) | | | |
| Male | 69 (48.6%) | 70 (41.7%) | 412 (45.8%) | 551 (45.5%) | | | |
| All | 142 | 168 | 900 | 1210 | 0.456 | 0.437 | 0.775 |
| Negative | 127 (91.4%) | 157 (96.9%) | 801 (92.5%) | 1085 (93%) | | | |
| Positive | 12 (8.6%) | 5 (3.1%) | 65 (7.5%) | 82 (7.0%) | | | |
| All | 139 | 162 | 866 | 1167 | 0.095 | 0.430 | 0.277 |
| No | 27 (19.0%) | 32 (19.0%) | 184 (20.4%) | 243 (20.1%) | | | |
| Yes | 93 (65.5%) | 117 (69.6%) | 627 (69.7%) | 837 (69.2%) | | | |
| Uncertain | 22 (15.5%) | 19 (11.3%) | 89 (9.9%) | 130 (10.7%) | | | |
| All | 142 | 168 | 900 | 1210 | 0.381 | 0.151 | 0.254 |
| Mean (SD) | 0.30 (1.153) | 1.87 (3.238) | 15.91 (3.605) | N/A | N/A | N/A | |
PTST- = Persistently negative tuberculin skin test; TSTC = Tuberculin skin test converter; TST + = tuberculin skin test positive at baseline.
*indicates P value that is significant after multiple testing correction.
1Statistical comparisons of these three groups must account for age group; see further detail in Additional file 1.
Individual epidemiological measures
| No | 122 (85.9%) | 140 (83.3%) | 698 (77.6%) | 960 (79.3%) | | | |
| Yes | 20 (14.1%) | 28 (16.7%) | 202 (22.4%) | 250 (20.7%) | | | |
| All | 142 | 168 | 900 | 1210 | 0.028 | 0.039 | 0.009 |
| No | 65 (45.8%) | 83 (49.4%) | 297 (33.0%) | 445 (36.8%) | | | |
| Yes | 77 (54.2%) | 85 (50.6%) | 603 (67.0%) | 765 (63.2%) | | | |
| All | 142 | 168 | 900 | 1210 | <0.0005* | <0.0005* | <0.0005* |
| No | 14 (9.9%) | 16 (9.5%) | 65 (7.2%) | 95 (7.9%) | | | |
| Yes | 128 (90.1%) | 152 (90.5%) | 835 (92.8%) | 1115 (92.1%) | | | |
| All | 142 | 168 | 900 | 1210 | 0.380 | 0.344 | 0.166 |
| Not Muzigo | 75 (52.8%) | 95 (56.9%) | 397 (44.4%) | 567 (47.1%) | | | |
| Muzigo | 67 (47.2%) | 72 (43.1%) | 497 (55.6%) | 636 (52.9%) | | | |
| All | 142 | 167 | 894 | 1203 | 0.004 | 0.148 | 0.001* |
| <1 day/wk | 1 (0.7%) | 2 (1.2%) | 19 (2.1%) | 22 (1.8%) | | | |
| 1-3 day | 6 (4.2%) | 7 (4.2%) | 38 (4.2%) | 51 (4.2%) | | | |
| 4-6 days | 7 (4.9%) | 5 (3.0%) | 24 (2.7%) | 36 (3.0%) | | | |
| daily | 129 (90.1%) | 153 (91.1%) | 816 (90.7%) | 1097 (90.7%) | | | |
| Total | 142 | 167 | 897 | 1206 | 0.740 | 0.536 | 0.593 |
| <1 | 3 (2.1%) | 5 (3.0%) | 19 (2.1%) | 27 (2.3%) | | | |
| 2-6 | 17 (12.1%) | 16 (9.5%) | 78 (8.8%) | 111 (9.3%) | | | |
| 7-12 | 70 (49.6%) | 87 (51.8%) | 511 (57.5%) | 668 (55.8%) | | | |
| 13-18 | 29 (20.6%) | 38 (22.6%) | 162 (18.2%) | 229 (19.1%) | | | |
| >18 | 22 (15.6%) | 22 (13.1%) | 118 (13.3%) | 162 (13.5%) | | | |
| Total | 141 | 168 | 888 | 1197 | 0.659 | 0.339 | 0.539 |
| Mean (SD) | 2.6 (2.773) | 2.64 (2.475) | 1.87 (2.056) | | <0.0005* | < 0.0005* | 0.029 |
| Mean (SD) | 3.44 (3.183) | 3.26 (2.541) | 2.70 (2.383) | | <0.0005* | < 0.0005* | 0.041 |
| Mean | 7.80 (5.235) | 6.76 (4.129) | 6.10 (3.672) | | <0.0005* | < 0.0005* | < 0.0005* |
| Mean | 1.67 (0.98) | 1.66 (0.867) | 1.61 (.896) | | 0.985 | 0.363 | 0.799 |
| | | ||||||
| Spouse | 6 (4.2%) | 10 (6.0%) | 122 (13.6%) | 138 (11.4%) | | | |
| Parent | 3 (2.1%) | 5 (3.0%) | 48 (5.3%) | 56 (4.6%) | | | |
| Sibling | 23 (16.2%) | 22 (13.1%) | 113 (12.6%) | 158 (13.1%) | | | |
| Avuncular | 24 (16.9) | 29 (17.3%) | 128 (14.2%) | 181 (15.0%) | | | |
| Child | 59 (41.5%) | 66 (39.3%) | 325 (36.1%) | 450 (37.2%) | | | |
| Grandparent/Child | 3 (2.1%) | 4 (2.4%) | 18 (2.0%) | 25 (2.1%) | | | |
| Unrelated | 21 (14.8%) | 27 (16.1%) | 126 (14.0%) | 174 (14.4%) | | | |
| Other relative | 3 (2.1%) | 5 (3.0%) | 20 (2.2%) | 28 (2.3%) | | | |
| Total | 142 | 168 | 900 | 1210 | 0.060 | 0.102 | 0.003 |
PTST- = Persistently negative tuberculin skin test; TSTC = Tuberculin skin test converter; TST + = tuberculin skin test positive at baseline.
*indicates P value that is significant after multiple testing correction.
Clinical characteristics of index case by clinical group
| No | 74 (53.2%) | 75 (45.5%) | 306 (34.7%) | 455 (38.4%) | | | |
| Yes | 65 (46.8%) | 90 (54.5%) | 576 (65.3%) | 731 (61.6%) | | | |
| All | 139 | 165 | 882 | 1186 | <0.005* | <0.005* | <0.005* |
| Normal | 18 (12.9%) | 9 (5.5%) | 40 (4.5%) | 67 (5.6%) | | | |
| Minimal | 22 (15.8%) | 22 (13.3%) | 81 (9.2%) | 125 (10.5%) | | | |
| Moderate | 58 (41.7%) | 76 (46.1%) | 305 (34.6%) | 439 (37.0%) | | | |
| Advanced | 41 (29.5%) | 58 (35.2%) | 456 (51.7%) | 555 (46.8%) | | | |
| All | 139 | 165 | 882 | 1186 | <0.005* | <0.005* | <0.005* |
| None | 4 (2.8%) | 3 (1.8%) | 14 (1.6%) | 21 (1.7%) | | | |
| Scanty | 5 (3.5%) | 1 (0.6%) | 11 (1.2%) | 17 (1.4%) | | | |
| 1+ | 13 (9.2%) | 4 (2.4%) | 21 (2.3%) | 38 (3.1%) | | | |
| 2+ | 31 (21.8%) | 39 (23.2%) | 89 (9.9%) | 159 (13.1%) | | | |
| 3+ | 89 (62.7%) | 121 (72%) | 765 (85%) | 975 (80.6%) | | | |
| Total | 142 | 168 | 900 | 1210 | <0.005* | <0.005* | <0.005* |
| Mean (SD) | 123.48 (155.876) | 118.75 (124.032) | 119.49 (119.597) | | 0.150 | 0.057 | 0.998 |
| Lineage 4 Uganda | 57 (46.3%) | 71 (47.7%) | 415 (54.0%) | 543 (52.2%) | | | |
| Lineage 4 non_Uganda | 49 (39.8%) | 60 (40.3%) | 280 (36.4%) | 389 (37.4%) | | | |
| Lineage 3 | 17 (13.8%) | 18 (12.1%) | 74 (9.6%) | 109 (10.5%) | | | |
| Total | 123 | 149 | 769 | 1041 | 0.308 | 0.101 | 0.269 |
PTST- = Persistently negative tuberculin skin test; TSTC = Tuberculin skin test converter; TST + = tuberculin skin test positive at baseline; CI = confidence interval.
Lineage 4 is also known as Euro-American and Lineage 3 is also known as Central Asian [20].
*indicates P value that is significant after multiple testing correction.
Ordinal regression analysis of PTST- vs TSTC and TSTC vs TST+
| | ||||||
|---|---|---|---|---|---|---|
| Intercept 1 | — | — | | 0.146 | (0.090, 0.24) | |
| Intercept 2 | — | — | | 0.400 | (0.25, 0.65) | |
| Age 2–5 vs 0-2 | 1.43 | (0.88, 2.32) | 0.15 | 1.34 | (0.82, 2.20) | 0.24 |
| Age 5–15 vs. 0-2 | 1.24 | (0.82, 1.89) | 0.31 | 1.04 | (0.68, 1.60) | 0.85 |
| Age 15+ vs 0-2 | 0.553 | (0.37, 0.84) | < 0.01 | 0.431 | (0.28, 0.66) | < 0.01 |
| No. of Windows | 1.145 | (1.09, 1.21) | < 0.01 | 1.097 | (1.02, 1.18) | < 0.01 |
| Sleep in Same Room | 0.559 | (0.43, 0.72) | < 0.01 | 0.66 | (0.48, 0.89) | < 0.01 |
| People in Home | 1.070 | (1.04, 1.10) | < 0.01 | 1.033 | (1.00, 1.07) | < 0.01 |
PTST- = Persistently negative tuberculin skin test; TSTC = Tuberculin skin test converter; TST + = tuberculin skin test positive at baseline; CI = confidence interval. Univariate model results show results for each variable one at a time, while the multivariable model includes all variables. Model parameterized as logit(Pr(y ≤ j)) = α + βx for j = 1 (PTST-), 2 (TSTC). Each OR shows the odds or PTST vs TSTC and also TSTC vs TST + .
Figure 1Boxplot illustrating distribution of risk scores by clinical group in A) children < 15 years old (range 0 to 9) and B) adults (range 0 to 10). PTST- (blue) = persistent TST negative, TSTC (green) = TST converter, and TST+ (red) = TST positive at baseline.
Number of individuals by clinical group considered “high risk” according to Mandalakas et al. criteria
| 2 years or less | 19/19 (100%) | 21/22 (95.5%) | 101/103 (98.1%) |
| >2 and equal to 5 | 27/27 (100%) | 24/24 (100%) | 93/93 (100%) |
| >5 or less than 15 | 62/65 (95.4%) | 45/47 (95.7%) | 231/237 (97.5%) |
| >15 | 23/31 (74.2%) | 68/75 (90.7%) | 410/467 (87.8%) |
“High risk” is defined as a pediatric risk score ≥5 out of 9, or an adult risk score ≥6 out of 10. Components of the risk score can be found in the Additional file 1, No statistically significant differences seen across clinical groups within age group (p > 0.05).
PTST- = Persistently negative tuberculin skin test; TSTC = Tuberculin skin test converter; TST + = tuberculin skin test positive at baseline.
Examination of “high risk” adults (age > 15) for key risk factors (N (%))
| Mean (SD) | 3.48 (3.25) | 3.10 (2.78) | 1.93 (2.03) | < 0.0005 | 0.056 | < 0.0005 |
| Mean (SD) | 4.26 (4.06) | 3.87 (3.23) | 2.77 (2.42) | 0.002 | 0.096 | < 0.0005 |
| Mean (SD) | 8.22 (7.30) | 7.30 (5.88) | 5.99 (3.93) | 0.198 | 0.259 | 0.030 |
| No | 12 (54.5%) | 28 (42.4%) | 155 (38.4%) | | | |
| Yes | 10 (45.5%) | 38 (57.6%) | 249 (61.6%) | 0.290 | 0.181 | 0.231 |
| Normal | 3 (13.6%) | 5 (7.6%) | 13 (3.2%) | | | |
| Minimal | 5 (22.7%) | 7 (10.6%) | 44 (10.9%) | | | |
| Moderate | 7 (31.8%) | 29 (43.9%) | 145 (35.9%) | | | |
| Advanced | 7 (31.8%) | 25 (37.9%) | 202 (50.0%) | 0.069 | 0.085 | 0.033 |
“High risk” defined as a score ≥ 6 out of 10 on risk score (based on Mandalakas et al. criteria).
PTST- = Persistently negative tuberculin skin test; TSTC = Tuberculin skin test converter; TST + = tuberculin skin test positive at baseline.